

# Beata Holkova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3586179/publications.pdf>

Version: 2024-02-01

7  
papers

171  
citations

1937457

4  
h-index

1719901

7  
g-index

7  
all docs

7  
docs citations

7  
times ranked

385  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2018, 59, 2588-2594.	0.6	22
2	Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 7542-7542.	0.8	4
3	Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2016, 128, 104-104.	0.6	14
4	Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. <i>Blood</i> , 2015, 126, 2798-2804.	0.6	118
5	Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study. <i>Blood</i> , 2015, 126, 377-377.	0.6	6
6	Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study. <i>Blood</i> , 2014, 124, 294-294.	0.6	3
7	A Phase 2 Study Of Single-Agent Brentuximab Vedotin For Front-Line Therapy Of Hodgkin Lymphoma In Patients Age 60 Years and Above: Interim Results. <i>Blood</i> , 2013, 122, 4389-4389.	0.6	4